Daiichi Sankyo Company (4568) Stock Overview
Manufactures and sells pharmaceutical products in Japan, the United States, Europe, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 4/6 |
| Past Performance | 3/6 |
| Financial Health | 6/6 |
| Dividends | 3/6 |
Rewards
Risk Analysis
4568 Community Fair Values
Create NarrativeSee what 19 others think this stock is worth. Follow their fair value or set your own to get alerts.
Daiichi Sankyo Company, Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥3,669.00 |
| 52 Week High | JP¥5,024.00 |
| 52 Week Low | JP¥3,036.00 |
| Beta | 0.25 |
| 1 Month Change | 8.55% |
| 3 Month Change | -0.24% |
| 1 Year Change | -24.65% |
| 3 Year Change | -21.03% |
| 5 Year Change | 15.20% |
| Change since IPO | 375.46% |
Recent News & Updates
Recent updates
Daiichi Sankyo Company's (TSE:4568) Upcoming Dividend Will Be Larger Than Last Year's
Sep 21
Daiichi Sankyo Company's (TSE:4568) Upcoming Dividend Will Be Larger Than Last Year's
Sep 05Daiichi Sankyo Company (TSE:4568) Has Announced That It Will Be Increasing Its Dividend To ¥39.00
Aug 22Daiichi Sankyo Company (TSE:4568) Is Paying Out A Larger Dividend Than Last Year
Aug 07Earnings Beat: Daiichi Sankyo Company, Limited Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
Aug 03Daiichi Sankyo Company (TSE:4568) Is Increasing Its Dividend To ¥39.00
Jul 24Daiichi Sankyo Company (TSE:4568) Is Increasing Its Dividend To ¥39.00
Jul 09We Think That There Are Issues Underlying Daiichi Sankyo Company's (TSE:4568) Earnings
Jun 27Daiichi Sankyo Company, Limited's (TSE:4568) P/E Is On The Mark
Jun 18Daiichi Sankyo Company, Limited Just Beat Earnings Expectations: Here's What Analysts Think Will Happen Next
Apr 30Is Daiichi Sankyo Company (TSE:4568) Using Too Much Debt?
Apr 06Daiichi Sankyo Company, Limited's (TSE:4568) P/E Is On The Mark
Feb 26Daiichi Sankyo Company, Limited Just Recorded A 8.3% EPS Beat: Here's What Analysts Are Forecasting Next
Feb 04Daiichi Sankyo Company, Limited's (TSE:4568) Intrinsic Value Is Potentially 93% Above Its Share Price
Jan 14Daiichi Sankyo Company, Limited's (TSE:4568) Share Price Matching Investor Opinion
Nov 25Daiichi Sankyo Company's (TSE:4568) Solid Earnings Are Supported By Other Strong Factors
Nov 07
Antibody-Drug Innovation And Strategic Partnerships Pave The Way For Significant Growth
Strategic R&D investments in antibody-drug conjugates and collaborations indicate potential future revenue growth and enhanced market share in oncology.Daiichi Sankyo Company, Limited Just Recorded A 223% EPS Beat: Here's What Analysts Are Forecasting Next
Nov 04Shareholder Returns
| 4568 | JP Pharmaceuticals | JP Market | |
|---|---|---|---|
| 7D | -8.4% | -2.6% | 1.4% |
| 1Y | -24.6% | -8.6% | 21.3% |
Return vs Industry: 4568 underperformed the JP Pharmaceuticals industry which returned -8.6% over the past year.
Return vs Market: 4568 underperformed the JP Market which returned 21.3% over the past year.
Price Volatility
| 4568 volatility | |
|---|---|
| 4568 Average Weekly Movement | 5.5% |
| Pharmaceuticals Industry Average Movement | 3.8% |
| Market Average Movement | 3.7% |
| 10% most volatile stocks in JP Market | 7.8% |
| 10% least volatile stocks in JP Market | 2.0% |
Stable Share Price: 4568's share price has been volatile over the past 3 months compared to the JP market.
Volatility Over Time: 4568's weekly volatility (6%) has been stable over the past year, but is still higher than 75% of JP stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1899 | 19,765 | Hiroyuki Okuzawa | www.daiichisankyo.com |
Daiichi Sankyo Company, Limited manufactures and sells pharmaceutical products in Japan, the United States, Europe, and internationally. The company offers Enhertu to treat patients with HER2 positive and low breast cancer, HER2 positive gastric or gastroesophageal junction adenocarcinoma, and HER2 positive solid tumors; Turalio, an oral small molecule that targets colony stimulating factor 1 receptor, KIT proto-oncogene receptor tyrosine kinase, and FMS-like tyrosine kinase 3 harboring an internal tandem duplication mutation for the treatment of symptomatic TGCT; Vanflyta, a FLT3 inhibitor to treat adult patients with acute myeloid leukemia; Injectafer, a ferric carboxymaltose injection for the treatment of iron deficiency; and DATROWAY to treat adult patients with breast cancer and NSCLC. It also provides Liziana and Savaysa, which are direct factor Xa inhibitors; Minnebro, Olmetec, Olmetec Plus, Rezaltas, Sevikar, and Sevikar HCT, which are antihypertensive agents; Nilemdo, an oral treatment that lowers cholesterol; Nustendi, a fixed-dose combination tablet of bempedoic acid and ezetimibe to reduce cholesterol; and Efient, an anti-platelet agent.
Daiichi Sankyo Company, Limited Fundamentals Summary
| 4568 fundamental statistics | |
|---|---|
| Market cap | JP¥6.79t |
| Earnings (TTM) | JP¥295.87b |
| Revenue (TTM) | JP¥1.92t |
Is 4568 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4568 income statement (TTM) | |
|---|---|
| Revenue | JP¥1.92t |
| Cost of Revenue | JP¥413.09b |
| Gross Profit | JP¥1.51t |
| Other Expenses | JP¥1.22t |
| Earnings | JP¥295.87b |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 159.85 |
| Gross Margin | 78.54% |
| Net Profit Margin | 15.37% |
| Debt/Equity Ratio | 12.7% |
How did 4568 perform over the long term?
See historical performance and comparisonDividends
Does 4568 pay a reliable dividends?
See 4568 dividend history and benchmarks| Daiichi Sankyo Company dividend dates | |
|---|---|
| Ex Dividend Date | Sep 29 2025 |
| Dividend Pay Date | Dec 10 2025 |
| Days until Ex dividend | 33 days |
| Days until Dividend pay date | 39 days |
Does 4568 pay a reliable dividends?
See 4568 dividend history and benchmarksCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/31 21:46 |
| End of Day Share Price | 2025/10/31 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2025/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Daiichi Sankyo Company, Limited is covered by 27 analysts. 16 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Atsushi Seki | Barclays |
| Koichi Mamegano | BofA Global Research |
| Hidemaru Yamaguchi | Citigroup Inc |